termination
and release agreement


 


This
Termination and Release Agreement (“Agreement”) is entered into as of this 8th day of November, 2018, by and among
Vilacto Bio, Inc., a Nevada corporation (the “Vilacto”), Pharma GP APS, a Denmark corporation, and its sole shareholder,
9 Heroes APS, a Denmark corporation (together “Pharma GP”).


 


WHEREAS,
on or about April 19, 2017, we entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Pharma GP and
its sole shareholder, 9 Heroes APS, a Denmark corporation, pursuant to which we agreed to purchase all of the outstanding shares
of Pharma GP for the purchase price of $6,000,000.00, payable as $3,000,000.00 in cash and the balance in shares of our common
stock;


 


WHEREAS,
the closing of the Purchase Agreement was originally scheduled to occur on May 31, 2017; however, Vilacto has been unable to raise
money needed to pay the purchase price under the Purchase Agreement;


 


WHEREAS,
the parties now desire to terminate and release each other and otherwise settle, compromise, dispose of, and release with finality,
all claims, demands and causes of action, arising out of the Purchase Agreement dated April 19, 2017;


 


NOW,
THEREFORE, in exchange for consideration, the adequacy of which is hereby acknowledged, the parties agree as follows:


 


	Termination.
Subject to the terms and conditions of this Agreement, as of the date hereof, the Parties hereby terminate the Purchase Agreement
and any and all rights, obligations or duties created thereunder.



 


	Coordination.
The parties agree to take whatever measures are necessary return to their respective positions as if the Purchase Agreement
were never executed.



 


	Mutual
Release. Except for the obligations set forth in this Agreement, each party hereby releases, remises, acquits and forever
discharges any other party to this Agreement and their related or controlled entities, and all of their directors, officers, members,
managers, partners, employees, servants, attorneys, assigns, heirs, successors, agents and representatives, past and present,
and the respective successors, executors, administrators and any legal and personal representatives of each of the foregoing,
and each of them, from any and all claims, demands, actions, causes of action, debts, liabilities, rights, contracts, obligations,
duties, damages, costs, expenses or losses, of every kind and nature whatsoever, and by whomever asserted, whether at this time
known or suspected, or unknown or unsuspected, anticipated or unanticipated, direct or indirect, fixed or contingent, or which
may presently exist or which may hereafter arise or become known, in law or in equity, in the nature of an administrative proceeding
or otherwise, for or by reason of any event, transaction, matter or cause whatsoever, with respect to, in connection with or arising
out of the Purchase Agreement or otherwise.



 


It
is understood by the parties that the facts with respect to which the foregoing release is given may hereafter turn out to be
other than or different from the facts now known to a party or the parties or believed by a party or the parties to be true, and
each party therefore expressly assumes the risk of the facts turning out to be so different and agrees that the foregoing release
shall be in all respects effective and not subject to termination or rescission by any such difference in facts.


 




    	 		 



    	 



    

 





	No Assignment.
The parties to this Agreement represent and warrant that neither they or their affiliated persons or entities have assigned or
transferred any claim or interest herein or authorized any other person or entity to assert any claim or claims on its behalf with
respect to the subject matter of this Agreement.



 


	Non-Disparagement.
The parties agree not to make any oral or written statements or otherwise take any action that is intended or may reasonably be
expected to disparage the reputation, business, prospects or operations of any other party to this Agreement.



 


	Confidentiality.
The parties agree that they will keep confidential all information and trade secrets of one another or any of its subsidiaries
or affiliates and will not disclose such information to any person without written prior approval or use such information for any
purpose. It is understood that for purposes of this Agreement the term “confidential information” is to be construed
broadly to include all material nonpublic or proprietary information. Vilacto shall promptly return any documents, records, data,
books or materials of Pharma GP or its subsidiaries or affiliates in its possession or control and any of its work papers containing
confidential information or trade secrets of Pharma GP or its subsidiaries or affiliates.



 


	Cooperation.
Each of the parties hereby agree to perform any and all acts and to execute and deliver any and all documents reasonably necessary
or convenient to carry out the intent and the provisions of this Agreement.



 


	Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without reference to the
principles of conflict of laws.



 


	Complete Agreement.
This Agreement represents the complete agreement among the parties concerning the subject matter in this Agreement and supersedes
all prior agreements or understandings, written or oral, including the Agreement, the Security Agreements, the Advances, or otherwise.
This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective
successors and legal representatives.



 


	Voluntary Agreement.
This Agreement has been entered into voluntarily and not as a result of coercion, duress, or undue influence. The parties acknowledge
that they have read and fully understand the terms of this Agreement and have been advised to consult with an attorney before executing
this Agreement.



 


	Successors and Assigns.
This Agreement shall be binding and inure to the benefit of the parties hereto, their predecessors, parents, subsidiaries and affiliated
corporations, all officers, directors, shareholders, agents, employees, attorneys, assigns, successors, heirs, executors, administrators,
and legal representatives of whatsoever kind or character in privity therewith.



 


	Counterparts.
This Agreement may be executed in counterparts, one or more of which may be facsimiles, but all of which shall constitute one and
the same Agreement. Facsimile signatures of this Agreement shall be accepted by the parties to this Agreement as valid and binding
in lieu of original signatures.



 


	Time for Performance.
The parties understand that time is of the essence with respect to each and every act required by this Agreement. Failure to perform
any provision hereof in strict accordance with the Agreement shall be deemed a material breach of the Agreement.





    	 	2	 



    	 



    

 





The
parties to this Agreement have executed this Agreement as of the day and year first written above.


 


VILACTO
BIO INC.


By
/s/ Gert Andersen


Printed
Name: Gert Andersen


Title:
CEO



 



PHARMA
GP APS


By
/s/ Gert Andersen


Printed
Name: Gert Andersen


Title:
CEO



 





9
HEROES APS


By
/s/ Gert Andersen


Printed
Name: Gert Andersen


Title:
CEO




    	 	3